-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Digital biomarkers: a powerful tool for Alzheimer's research
Sep 14, 2018
The convergence of analytics technology, wearable devices, and machine learning has led to a new form of data for clinical research: digital biomarkers.
A digital biomarker is a quantifiable indicator of a patient’s physiological and/or behavioral state captured via any number of patient-wearable connected devices, including but not limited to, wearable (i.e. blood pressure monitors, actigraphy devices or multi-sensor patches) and implantable (i.e. pacemakers, continuous glucose monitors), technologies.
The evolution of these devices, and the ability to remotely capture this data is providing researchers and physicians with a windfall of novel near and real- time insights. That’s good news for Alzheimer’s Disease (AD) research where the impact of this data will be profound:
24/7 data capture
Wearable and implantable devices can continuously capture data with little or no required patient interaction, providing researchers with hundreds or thousands of data points per day related to the patient’s condition. Additionally, many of these devices now have real-time, or near real time, communication capabilities, providing researchers and caregivers richer data sets, trending information, and details regarding specific events. This information can be used to assess safety and efficacy endpoints as well as to development of predictive algorithms along with tracking physiological endpoints, such as blood pressure and heart rate, and research teams can track behavioral trends related sleep patterns, activity levels, diet, and day-to-day habits. In combination with cognitive surveys and other validated instruments conducted via digital devices, this unbiased and ongoing flow of data (data flow) will provide detailed and accurate profile of a patients’ physical and mental status over time.
In studies focused on prodromal or pre-symptomatic patients, such data, in combination with pharmacogenomics, can deliver new insights into the early progress of this disease. It will also be crucial for identifying which digital biomarkers – or combinations of biomarkers (i.e. sleep patterns, WASO and nocturnal blood pressure dipping) -- are the strongest indicators of early AD risk.
These discoveries could speed the clinical recruiting process and reduce the high rate of screen failures for future AD trials.
Figure 1: Digital Health Use in Clinical Trials for Patient Monitoring
Less disruptive
In any clinical study, researchers need to balance the need for patient data versus patient burden. Frequent site visits and demands for additional tests can cause participants to drop out of trials, or to fail to comply with the treatment.
Capturing digital biomarker data via connected devices may reduce this risk. When researchers gather information remotely and automatically, it lessens the need for patient site visits while delivering a more consistent quantity and quality of data. These devices can also add value for patients and caregivers who want to track their status, and/or receive alerts or reminders to take a medicine or complete tasks.
In AD clinical trials, as well as long-term observational studies, this is huge benefit. Prodromal patients in particular are difficult to find, so retention of every patient is vital. For studies tracking patients in the later stages of dementia, reducing site visits lessens the burden for patients and caregivers, allowing researchers to capture data in the homecare setting, where patients are less likely to become agitated, aggressive, or more confused.
Reduced overhead
Site monitoring is a significant cost in clinical development. Clinical Research Associates (CRAs) spend hundreds of hours visiting sites to monitor and validate data capture and transcription because so much information is collected from patients during face-to-face visits. Use of validated digital tools to automatically and accurately collect endpoint data and transfer it to the clinical database will decrease site management requirements while increasing data collected and improving data accuracy.
Going forward: We must make better use of data
Regulators are increasingly supportive of using data captured from wearables and other connected devices in clinical trials because they see the value these endpoints bring to our understanding of disease progression.
The challenges now include determining which technologies and devices available now can deliver useful data today, how best to use this data to support safety and efficacy endpoints and how to combine these data streams into data sets that can be used to develop more useful algorithms to guide research and treatment tomorrow. Every incremental advance in the speed and quantity of data we capture via connected digital health devices creates new opportunities for the AD research community to advance our understanding on this disease.